In 2009, the first genome-wide association study (GWAS) for major depressive disorder (MDD) highlighted an association with PCLO locus on chromosome 7, although not reaching genome-wide significance level. In the present study, we revisited the original GWAS after increasing the overall sample size and the number of interrogated SNPs. In an analysis comparing 1,942 cases with lifetime diagnosis of MDD and 4,565 controls, PCLO showed a genome-wide significant association with MDD at SNP (rs2715157, p = 2.91 × 10 −8 ) and gene-based (p = 1.48 × 10 −7 ) level. Our results confirm the potential role of the PCLO gene in MDD, which is worth further replication and functional studies.
In 2009, as part of the Genetic Association Information Network (GAIN) initiative, we published (Sullivan et al., 2009) the first genome-wide association study (GWAS) for major depressive disorder (MDD). The participants were assembled from two large Dutch cohorts: the Netherlands Study of Depression and Anxiety (NESDA) and the Netherlands Twin Registry (NTR). A comparison between 1,738 cases with lifetime diagnosis of DSM-IV MDD and 1,802 screened controls highlighted a signal overlapping the region of PCLO gene, although variants identified did not reach genome-wide significance. Importantly, our result received strong support (though not reaching formal significance) from Australian data similarly ascertained from a population twin registry (Sullivan et al., 2009 ). Based on the promising role of PCLO encoding a cytoskeletal protein located in the presynaptic active zone, the original finding was followed by replication efforts, with positive (Hek et al., 2010) and negative (Verbeek et al., 2013) results. In the present study, we revisited the original GWAS after introducing important improvements. The overall sample size was almost doubled, adding newly genotyped participants from the original cohorts, consisting mainly of a large number of controls carefully screened using several sources of information including longitudinal assessments and family history (Boomsma et al., 2008) . The number of interrogated SNPs was increased by re-genotyping the majority of participants on a newer array and by imputing variants with a denser reference panel (1,000 Genomes Phase 3).
The present sample consisted of 6,507 participants (63.1% females) of European ancestry from NESDA and NTR. Lifetime MDD diagnoses according to DSM-IV were ascertained using the Composite Interview Diagnostic Instrument. Healthy controls were screened based on absence of any lifetime psychiatric disorder (NESDA), no report of MDD, no known first-degree relatives with MDD, and a low factor score based on a multivariate analysis of depressive complaints, anxiety, neuroticism, and somatic anxiety (Boomsma et al., 2000) . After applying stringent quality control criteria (Supplementary Methods), we performed a GWAS comparing 1,942 cases and 4,565 controls, Note: EAF = effect allele frequency; OR = odds ratio; 95% CI = 95% confidence interval. a SNP positions are according to NCBI Human Genome Build 37.
adjusting for gender and 10 ancestry-informative principal components. Family structure was taken into account using a sandwich estimator implemented in Plink.
The estimated LD score regression intercept was 1.03, suggesting no appreciable inflation of the test statistics attributable to unaccounted stratification ( Figure S1 ). The analysis identified 17 genome-wide significant SNPs (p < 5 × 10 −8 ; Figure 1 ) spanning the PCLO gene on chro-mosome 7 with rs2715157 emerging as the SNP most significantly associated with MDD (p = 2.91 × 10 −8 ); its minor allele (A) was negatively associated with MDD (OR = 0.79). The PCLO lead SNP identified in the original GWAS, rs2715148 showed the same effect size as in the original analysis but was now genome-wide significantly associated with MDD (p = 3.89 × 10 −8 ; OR = 0.79). Similarly, the non-synonymous coding SNP rs2522833 reported the 268 TWIN RESEARCH AND HUMAN GENETICS same effect size of the original GWAS but a smaller p value (OR = 1.26, p = 8.29 × 10 −8 ). These SNPs were highly correlated with rs2715157 (r 2 > 0.8; Figure 2 ). Furthermore, in silico functional annotation of the top SNPs showed possible functional effects. The PCLO SNP rs2715157 alters the sequence of six protein-binding motifs including Pou3f2, indicating a possible effect on the activation of corticotrophin releasing hormone. It also bound to the P300 protein known to regulate gene transcription. SNPs rs2751161 and rs2522835 were contained in a DNase I hypersensitive site suggesting open chromatin, although they did not alter any of the transcription factor binding sites present in the promoter flanking region. Together, these data indicate these SNPs might have direct functional roles (Table S1 ). Finally, p values of analyzed SNPs were used to perform a gene-based test (Supplementary Methods), and PCLO showed a significant association with MDD (p = 1.48 × 10 −7 ), even considering a stringent multiple comparison adjustment accounting for 20,000 genes (p = 2.5 × 10 −6 ).
These findings provide evidence for an association between the PCLO gene and MDD that now clearly reaches genome-wide significance. An important factor was the increase in sample size. Indeed, the effect size detected for SNPs present in both the original and current analyses were exactly the same, but the improved precision in their estimation impacted the test significance. Allele frequencies were also the same for SNPs present in both analyses, suggesting no probable effect on results due to technical differences between the genotyping platforms used in the two GWASs. Nevertheless, imputation allowed us to examine additional SNPs in the same LD block previously not included.
It is important to note that the effectiveness of sample size increase may have been amplified by the clinical homogeneity of the sample and the detailed phenotyping procedure. Recently, the assembling of massive samples has enabled the success of GWAS for depression (Hyde et al., 2016; Okbay et al., 2016) , overcoming the problematic phenotypic heterogeneity of this trait. Nevertheless, large collaborative studies clearly identified substantial heterogeneity among different MDD datasets as indexed by cross-dataset SNPcorrelations smaller than one (Lee et al., 2013) , possibly indicating the presence of dataset specific variants. Therefore, collecting a larger sample size, although on a smaller scale, in more homogeneous populations still constitutes a valuable complementary effort aimed at clarifying specific genetic signals that might be overshadowed by the heterogeneity arising from the addition of each new dataset in meta-analytic studies.
To conclude, in our current genome-wide study of MDD, we found confirming evidence of a genome-wide significant association with the PCLO gene. Our findings, together with previous biological evidence (Ahmed et al., 2015; Waites et al., 2011) , suggest the importance of the PCLO gene to MDD, which is worth further replication and functional studies.
